TP-03, 0.25%
TRS-009
Phase 3 small_molecule completed
Quick answer
TP-03, 0.25% for Blepharitis is a Phase 3 program (small_molecule) at Tarsus Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tarsus Pharmaceuticals
- Indication
- Blepharitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed